Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions announced poster presentations with data on two of its skin cancer gene expression profile tests at the 18th Annual Winter Clinical Dermatology Conference, taking place virtually from Jan. 15 – 24, 2021. President and chief executive officer, Derek Maetzold, will also participate in the meeting’s 2021 View for Dermatology Industry Panel,” scheduled to take place on Jan. 23, from 2:10 p.m. – 2:50 p.m. Eastern time. Poster information is as follows: The virtual poster is entitled, “Identifying predictors of sentinel lymph node metastasis in cutaneous melanoma patients using molecular and clinicopathologic high-risk features. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node (SLN) positivity, independent of traditional staging factors. Study methods and findings: For 3,093 patients with T1-T4 cutaneous melanoma, authors used decision tree analysis to determine which molecular and clinicopathologic features best stratify SLN positivity risk; DecisionDx-Melanoma was the most important factor in distinguishing between high and low SLN-positivity rates (p<0.001). DecisionDx® DiffDx™-Melanoma: The virtual poster is entitled, Performance of a 35-gene expression profile test in suspicious pigmented lesions of the head and neck. DecisionDx DiffDx-Melanoma is designed to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions. Study methods and findings: As melanoma of the head and neck often require special consideration with respect to staging and treatment decisions, early and accurate detection is especially critical for these lesions. This study evaluated DecisionDx DiffDx-Melanoma’s accuracy in classifying pigmented lesions on the head and neck.; DecisionDx DiffDx-Melanoma was used to independently assess 105 lesions located on the head and neck in adults age 18 and up; DecisionDx DiffDx-Melanoma classified these lesions as benign (n=54, 51.4%), malignant (n=48, 45.7%), and intermediate-risk (n=3, 2.9%) with accuracy metrics of 98.0% sensitivity, 100% specificity, 100% PPV and 98.2% NPV.; The test’s performance in the head and neck lesion population is similar to its performance in pigmented lesions in the rest of the body in the overall adult population.; DecisionDx DiffDx-Melanoma demonstrated its ability to be an effective tool for refining melanoma diagnoses on the head and neck and therefore improving downstream management decisions, as indicated by its high sensitivity and specificity in this study.